Mark Morrow
Impact in
- Immunology and Allergy top 10%
- Cell Adhesion Molecules Research
- Oncology top 10%
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
Papers in
- Oncology 6
- Cancer Treatment and Pharmacology 3
- Lung Cancer Research Studies 2
-
- Proteoglycans and glycosaminoglycans research 2
- Co-authors
- S. Gail Eckhardt (6 shared papers)Todd M. Pitts (3 shared papers)Daniel L. Gustafson (5 shared papers)Lia Gore (6 shared papers)M. Basche (4 shared papers)Scott N. Holden (3 shared papers)John J. Tentler (1 shared paper)Sabine Eckhardt (4 shared papers)
- Journals
- Clinical Cancer Research (4 papers)Annals of Oncology (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Molecular Cancer Therapeutics (2 papers)Journal of Clinical Oncology (1 paper)
- Partner nations
- United StatesAustraliaCanada
In The Last Decade
Mark Morrow
15 papers receiving 677 citations
Peers
Comparison fields: 5 of 61
- Immunology and Allergy 64
- Oncology 254
- Cancer Research 123
- Cell Biology 142
- Molecular Biology 357
Countries citing papers authored by Mark Morrow
This map shows the geographic impact of Mark Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Morrow more than expected).
Fields of papers citing papers by Mark Morrow
This network shows the impact of papers produced by Mark Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Morrow. The network helps show where Mark Morrow may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Morrow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 109 | |
| 2 | 2006 | 104 | |
| 3 | 2006 | 82 | |
| 4 | 2000 | 78 | |
| 5 | 2009 | 64 | |
| 6 | 2010 | 62 | |
| 7 | 2006 | 38 | |
| 8 | 2007 | 34 | |
| 9 | 2007 | 32 | |
| 10 | 2007 | 22 | |
| 11 | 2008 | 21 | |
| 12 | Carcinoembryonic antigen in patients with squamous cell carcinoma of the cervix uteri and vulva. | 1974 | 14 |
| 13 | 2006 | 14 | |
| 14 | Verapamil enhances antitumor activity without increasing myeloid toxicity. | 1987 | 10 |
| 15 | 2008 | 10 |
About Mark Morrow
Mark Morrow is a scholar working on Oncology, Cell Biology, Immunology and Allergy, Pharmacology and Epidemiology, having authored 15 papers that have together received 694 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (3 papers), Lung Cancer Research Studies (2 papers), Proteoglycans and glycosaminoglycans research (2 papers), Acute Myeloid Leukemia Research (1 paper), Cell Adhesion Molecules Research (1 paper), Immunotherapy and Immune Responses (1 paper), Neuroendocrine Tumor Research Advances (1 paper) and Protease and Inhibitor Mechanisms (1 paper). The work is most often cited by research in Immunology and Allergy (64 citations), Oncology (254 citations), Cancer Research (123 citations), Cell Biology (142 citations) and Molecular Biology (357 citations). Mark Morrow has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include S. Gail Eckhardt, Todd M. Pitts, Daniel L. Gustafson, Lia Gore, M. Basche, Scott N. Holden, John J. Tentler, Sabine Eckhardt, S. Gail Eckhardt and Teresa Troiani. Their work appears in journals such as Clinical Cancer Research, Annals of Oncology, Cancer Chemotherapy and Pharmacology, Molecular Cancer Therapeutics and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.